Semarion Unveils SemaCyte Multiplexing Platform to Revolutionize Drug Discovery
Source-news-medical.net Introduction of SemaCyte Multiplexing Platform Semarion Ltd, a pioneering University of Cambridge spin-out company, has introduced its latest innovation, the SemaCyte Multiplexing Platform . This cutting-edge platform, an extension of the existing SemaCyte Microcarrier technology, aims to revolutionize in vitro drug discovery processes by utilizing optical barcoding to accelerate screening procedures. Features and Benefits of the Multiplexing Platform The SemaCyte Multiplexing Platform is specifically designed to enhance the quality and efficiency of drug discovery workflows. By allowing for in situ multiplexing of adherent cells using proprietary microcarriers, the platform enables researchers to generate high-quality data at an unprecedented speed. Each microcarrier is equipped with optical barcodes, facilitating the tagging and differentiation of individual cells and cell types while preserving their natural morphology. This innovative approach not...